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Previewssignaling pathways that turn on PRC2-
silenced genes may not be sufficient to
reliably induce expression of their targets.
When PRC2 activity is low, as in Eed or
Suz12mutants, target genes are no longer
reliably silenced, and such a result can
lead to incorrect execution of develop-
mental programs (Chamberlain et al.,
2008; Pasini et al., 2007). Indeed, Eed
mutant ESCs are prone to differentiation
in culture, suggesting that PRC2 is neces-
sary for ESCs to robustly carry out the self-
renewal program. Thus, one possibility is
that the ratio of different PRC2 complexes
occupying each target gene may be
important in determining whether a sig-
naling pathway will trigger maintenance
of or release from silencing, thus allowing
cells to silence or upregulate a subset of
PRC2 targets in response to particular
developmental cues.
The near-perfect overlap between
Jarid2 and PRC2 in ESCs argues that it
is not simply the presence or absence of
Jarid2 that regulates PRC2 target gene
activity. However, in addition to Jarid24 Cell Stem Cell 6, January 8, 2010 ª2010 Eland Mtf2 and other Pcl homologs, there
are several other sources of variability
between PRC2 complexes (Simon and
Kingston, 2009). Specifically, there are
two related genes encoding H3K27
KMTs, Ezh2 and Ezh1, both of which
associate with Eed and Suz12 and there
are four isoforms of Eed that differ in
their N-termini because of alternative
translation-start-site usage. Thus, there
is potential for considerable combinatorial
complexity of PRC2 complexes. Once the
composition and activities of different
PRC2 complexes is determined, and the
factors that direct these different com-
plexes to their target genes are identified,
it may be possible to fully understand how
PRC2 is utilized to control so many genes
in such a wide variety of developmental
contexts.
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A recent study in Nature Cell Biology, Wellner et al. (2009) identifies ZEB1, a known promoter of tumor inva-
sion, as a negative regulator of miRNA clusters that target stem cell factors. These findings provide new
insight into the network of transcription factors and miRNAs that regulate cancer stem cells.Treatment of human cancers is compli-
cated because the majority of cancers
become metastatic and/or develop resis-
tance to therapy. Two concepts that may
explain tumor progression and acquisition
of a therapy-resistant phenotype have
received wide attention. In the first con-
cept, tumor cells gain an invasive pheno-
type by a process that resembles the
epithelial tomesenchymal transition (EMT)
found during embryonic development and
wound healing. During EMT, cells change
morphology, lose polarity, and becomemobile. The second concept is based on
the recognition that many human cancers
containa rarepopulationofcells that exhibit
stem cell properties and drive neoplastic
growth. Recent data have connected the
two concepts in breast cancer by demon-
strating that induction of EMT in both
mammaryepithelialcellsaswell as inbreast
cancer cells causes upregulation of stem
cell markers (Mani et al., 2008). Conversely,
EMTmarkers were found to be enriched in
stem cells isolated from either mammary
glands or mammary carcinomas.miRNAs have emerged as powerful
regulators of differentiation, and a number
of miRNAs have been shown to be either
highly expressed or excluded from stem
cells. miRNAs that are highly expressed
in stem cells include the miR-302371
cluster; expression of miR-302 alone in
human skin cancer cells induced a pheno-
type that included properties of pluripo-
tent embryonic stem cells (Lin et al.,
2008). Examples of miRNAs excluded
from embryonic stem cells are let-7 (Yu
et al., 2007) and miR-145, which targets
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Figure 1. Network of miRNAs Regulating
EMT and Stemness
Three miRNAs/miRNA clusters (shown in black)
regulate expression of stem cell factors and of
ZEB1 (miRNA targets are shown in red). ZEB1 is
a central regulator functionally connecting EMT
with stem cell maintenance because of its ability
to bind to E-boxes in the promoters of E-cadherin
and all three miRNA gene clusters.
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PreviewsSox2, Oct4, and Klf4 (Xu et al., 2009).
These data provide evidence that miR-
NAs, some of which are deregulated in
many human cancers, are also markers
and powerful regulators of stem cells
and cancer stem cells.
Recently, members of the miR-200
familyofmiRNAs (miR-200a, -200b, -200c,
-141, and -429) were recognized to
be regulators of the epithelial pheno-
type and, hence, to be regulators of EMT
(Gregory et al., 2008a; Park et al., 2008).
miR-200 was shown to target two E-box-
binding inhibitors of E-cadherin, ZEB1
and ZEB2, raising the question as to
what mechanism regulates expression of
miR-200 family members. Subsequently,
both ZEB1 and ZEB2 were reported to
be part of a double-negative feedback
loop, in that they participate in the repres-
sion of the expression of all five miR-200
family members (Gregory et al., 2008b).
Given that miR-200 is a powerful regulator
of EMT, and because EMT has been con-
nected to the regulation of stemness, it
seemed merely a question of when, not
if, someone would demonstrate that
miR-200 regulates the emergence of
stem cells and cancer stem cells, in addi-
tion to EMT.
To this end, Clarke and colleagues
recently identified a set of miRNAs thatare not expressed in either mammary
epithelial stem cells or in enriched breast
cancer stem cells (Shimono et al., 2009).
Further, the authors identified and vali-
dated that the stem cell factor BMI1 is
a target for themiR-200 family of miRNAs.
Overexpression of miR-200c, either in
normal stem cells or in cancer stem cells,
reduced their clonogenic and tumor-initi-
ating activities.
The Shimono et al. findings raise addi-
tional questions. First, is BMI1 the only
stem cell-relevant target of miR-200? It
seemed unlikely that miR-200 would exert
its function by targeting only one gene,
especially given that both ZEB1 and
ZEB2 were known to be efficiently tar-
geted bymiR-200. Second,what prevents
miR-200 expression in stem cells, but not
more differentiated progeny?
In a report from a recent issue of Nature
Cell Biology, Wellner et al. (2009) offers
some answers to these questions and
provides further evidence of an miRNA-
mediated connection between EMT and
cancer stem cells. The authors demon-
strated that ZEB1 is preferentially ex-
pressed in the invasive front of pancreatic
cancer samples, similar to their previous
finding in colon cancer (Spaderna et al.,
2006). Consequently, knockdown of
ZEB1 in pancreatic cancer cell lines
reduced both invasion and metastasis in
an orthotopic mouse xenograft model.
In addition, knockdown of ZEB1 also
caused a reduction in tumorigenicity of
the cancer cells, based on the size and
number of tumors that formed in recipi-
ents, even under serial dilution conditions.
Other traits attributed to cancer stem
cells were also diminished, including
the frequency of CD24-positive cells (a
marker for pancreatic cancer stem cells),
the ability to form spheres in culture, and
chemoresistance. Furthermore, expres-
sion of a number of miRNAs was affected
in these cells. Most notably, members of
three miRNA gene clusters were upregu-
lated in ZEB1 knockdown cells. They
included two members of the miR-200
family, miR-183 and miR-203. Interest-
ingly, all three miRNA clusters carry
E-boxes in their promoters and were
found to be repressed by ZEB1. In line
with the predicted function, expression
of both miR-203 and miR-183 decreased
the sphere-forming capacity of pancreatic
cancer cells. Consistent with the recent
work by Shimono et al. (2009) on breastCell Stem Cecancer and normal stem cells, both
miR-200 and members of the miR-183-
96-182 cluster were also identified as
regulating cancer stem cells in pancreatic
cancer, suggesting a mechanism that is
not restricted to one cancer type. BMI1
was confirmed as a major target of
miR-200 regulating cancer stem cells.
However, BMI1 was also found to contain
seed matches for two other miRNAs in
its 30 UTR, and it was experimentally
validated asa target formiR-200,miR-183,
and miR-203. Remarkably, evidence was
provided to suggest that other pluripo-
tency factors such as Sox2 and Klf4 are
also targets of miR-200, pointing at
a complex network of multiple miRNAs
that influence stem cell regulators, with
ZEB1 at the center of multiple negative
feedback loops (Figure 1). Although the
Wellner study focused on ZEB1, it is likely
that ZEB2 has similar activity, given that
both ZEB1 and ZEB2 bind to E-boxes in
the promoters of the two miR-200 gene
clusters (Gregory et al., 2008b).
Not all human cancers contain cancer
stem cells. However, the data on the
parallels on the roles of miRNAs in normal
tissue stem cells and cancer stem cells
are consistent with the existence of
cancer stem cells in breast, colon, and
pancreatic cancer and point at widely
overlapping signaling pathways that regu-
late differentiation and maintenance of
both populations. In addition, this work
has reinforced the notion that miRNAs
often act as part of negative feedback
loops. Thus, targeting a combination of
protein and RNA components of these
loops could open up novel therapeutic
opportunities for many cancers that resist
conventional treatment.REFERENCES
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Resistance of brain tumors to therapy and their eventual recurrence is attributed to stem-like cells. In this
issue of Cell Stem Cell, a high-throughput kinome-wide screen (Wurdak et al., 2010) has identified TRRAP,
a kinase-related protein, as being required for stem cell character in gliomas.The prognosis for treatment of glioblas-
tomas remains dismal (a little more than
1 year), and research toward a better
understanding of the biology of thera-
peutic resistance for this disease is
actively ongoing. One proposed reason
for the poor response to treatment is the
existence of a small subpopulation of
resistant cells within these tumors that
survive treatment and repopulate the
tumor. These resistant cells have proper-
ties similar to stem cells, and isolation
of this subpopulation, referred to as brain
tumor-initiating cells (BTICs) or brain
tumor stem-like cells, was first achieved
by utilizing the hematopoietic stem cell
marker CD133 (Singh et al., 2004). In their
study, the authors showed that this cell
population from human glioblastoma
samples could regenerate tumors with
phenotypes comparable to those from the
patient more efficiently than their CD133-
negative counterparts. These stem-like
cells contribute to the glioma’s resistance
to therapy (Bao et al., 2006). The data
suggest that the stem cell-like properties
of BTICs are important factors mediating
tumor resistance and recurrence and
that novel strategies that specifically tar-
get this population may be essential for
improved therapeutic outcomes. Several
signaling pathways including Notch, Shh,
and PI3K are known to regulate the
activity of normal neural stem cells (Stiles
and Rowitch, 2008), implying that kinasesregulate this phenotype. These signaling
pathways similarly regulate the activity of
BTICs and may represent one approach
to directly target BTICs. The bone mor-
phogenic proteins (BMPs) induce differ-
entiation of neural stem cells into mature
astrocytes and BMP4 induces differentia-
tion of BTICs in gliomas (Piccirillo et al.,
2006). By enforcing the differentiation of
BTICs in this manner, one might predict
that tumor recurrencewould be less likely,
because the stem cell properties of
the tumor cells should be lost in the
more mature progeny. This approach
was successfully employed in the treat-
ment of promyelocytic leukemia (Wang
et al., 1998).
In this issue of Cell Stem Cell, a manu-
script from theSchultz laboratory (Wurdak
et al., 2010) provides further insight into
this phenomenon and important experi-
mental evidence to justify targeting of
BTICs with differentiating factors. The
authors used a phenotypic high-through-
put shRNA library screen targeting the
kinome to identify genes involved in the
maintenance of ‘‘stemness’’ in gliomas,
withBMP4 treatment as a positive control.
The authors identified many expected
kinases such as IGFR, as well as MAP
and SRC family kinases. In addition, they
identified TRRAP, an adaptor protein
with homology to the PIKK kinases
but lacking intrinsic kinase activity, as
playing a role in the differentiation phe-notype in glioblastoma stem-like cells.
TRRAP is thought to regulate many
biologic functions including chromatin
remodeling, embryonic development,
oncogenic transformation through c-Myc
and E2F, as well as cell cycle progression.
The authors report that knockdown of
TRRAP in BTICs (grown as a monolayer
on laminin) resulted in many phenotypic
changes consistent with loss of stem
cell characteristics (Figure 1) including
decreased neurosphere formation in
culture, decreased tumor formation upon
transplantation into recipient mice, in-
creased sensitivity to temozolomide and
radiation therapy, and alteration of mar-
kers associated with differentiation such
as loss of Nestin and Sox2 with gain of
GFAP and TuJ1. The data imply that
TRRAP loss depletes the stem-like pool of
BTICs in vitro and mirrors the effects first
reported for BMP4 (Piccirillo et al., 2006).
Given the presented data on loss of func-
tion, one might expect overexpression of
TRRAP to promote stem cell character
and tumorigenic potential in these BTICs;
in fact, TRRAP gene expression was
elevated in the gliomas analyzed in this
study.
The effects on proliferation and differ-
entiation induced by TRRAP knockdown
appeared to be mediated in part by
suppression of transcriptional activity for
the mitotic cyclin A2 with associated
epigenetic modifications at the cyclin
